NO972913L - Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser - Google Patents

Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser

Info

Publication number
NO972913L
NO972913L NO972913A NO972913A NO972913L NO 972913 L NO972913 L NO 972913L NO 972913 A NO972913 A NO 972913A NO 972913 A NO972913 A NO 972913A NO 972913 L NO972913 L NO 972913L
Authority
NO
Norway
Prior art keywords
treatment
pct
recombinant
antagonists useful
conditioned
Prior art date
Application number
NO972913A
Other languages
English (en)
Other versions
NO972913D0 (no
NO324181B1 (no
Inventor
Robert S Ames
Edward Robert Appelbaum
Irwin M Chaiken
Richard M Cook
Mitchell Stuart Gross
Stephen Dudley Holmes
Lynette Jane Mcmillan
Timothy Wayne Theisen
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO972913(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,420 external-priority patent/US5683892A/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of NO972913D0 publication Critical patent/NO972913D0/no
Publication of NO972913L publication Critical patent/NO972913L/no
Publication of NO324181B1 publication Critical patent/NO324181B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
NO19972913A 1994-12-23 1997-06-20 Monoklonalt antistoff spesifikt for human IL-5 og fragmenter derav, hybridoma cellelinjer, endret antistoff, immunolglobulin-tungkjede-komplementaritetsbestemmende region, nukleinsyremolekyl, kimaert antistoff, farmasoytisk preparat omfattende endret antistoff, anvendelse av antistoff, isolert nukleinsyresekvens, rekombinant plasmid, vertcelle, fremgangsmate for a fremstille et endret antistoff og metoder for a bestemme human IL-50. NO324181B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (3)

Publication Number Publication Date
NO972913D0 NO972913D0 (no) 1997-06-20
NO972913L true NO972913L (no) 1997-08-19
NO324181B1 NO324181B1 (no) 2007-09-03

Family

ID=27408594

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19972913A NO324181B1 (no) 1994-12-23 1997-06-20 Monoklonalt antistoff spesifikt for human IL-5 og fragmenter derav, hybridoma cellelinjer, endret antistoff, immunolglobulin-tungkjede-komplementaritetsbestemmende region, nukleinsyremolekyl, kimaert antistoff, farmasoytisk preparat omfattende endret antistoff, anvendelse av antistoff, isolert nukleinsyresekvens, rekombinant plasmid, vertcelle, fremgangsmate for a fremstille et endret antistoff og metoder for a bestemme human IL-50.
NO2015027C NO2015027I2 (no) 1994-12-23 2015-12-18 Mepolizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2015027C NO2015027I2 (no) 1994-12-23 2015-12-18 Mepolizumab

Country Status (22)

Country Link
US (1) US6129913A (no)
EP (1) EP0800536B1 (no)
JP (2) JP2001523083A (no)
CN (1) CN100391977C (no)
AT (1) ATE346867T1 (no)
AU (1) AU708951B2 (no)
BR (1) BR9510499B1 (no)
CA (1) CA2208503C (no)
CZ (1) CZ297045B6 (no)
DE (1) DE69535319T2 (no)
DK (1) DK0800536T3 (no)
ES (1) ES2277336T3 (no)
FI (1) FI119374B (no)
HK (1) HK1003651A1 (no)
HU (1) HU222992B1 (no)
LU (1) LU92912I2 (no)
MX (1) MX9704779A (no)
NL (1) NL300787I2 (no)
NO (2) NO324181B1 (no)
NZ (1) NZ301916A (no)
PL (1) PL194312B1 (no)
WO (1) WO1996021000A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN1326879C (zh) * 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP1682571A4 (en) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd BICOORDIN PATTERN AND METHODS OF USE
KR101206318B1 (ko) * 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
JP4335286B2 (ja) 2008-02-08 2009-09-30 ファナック株式会社 部品保護機能を備えたロボット制御装置及びロボット制御方法
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
AU2011209713B2 (en) * 2010-01-28 2014-04-03 Glaxo Group Limited CD127 binding proteins
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
EA037487B1 (ru) 2015-08-24 2021-04-02 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Биофармацевтические композиции
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
US11111292B2 (en) * 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
UY37747A (es) 2017-05-26 2019-01-02 Glaxosmithkline Ip Dev Ltd Composiciones para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados
TWI801425B (zh) * 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
WO2020119728A1 (zh) * 2018-12-12 2020-06-18 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA929328B (en) * 1991-12-02 1993-07-20 Fluor Corp Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
AR248044A1 (es) * 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) * 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
CZ297045B6 (cs) 2006-08-16
WO1996021000A2 (en) 1996-07-11
HK1003651A1 (en) 1998-11-06
NO2015027I2 (no) 2016-01-04
FI972703A0 (fi) 1997-06-23
BR9510499A (pt) 1999-03-30
AU4745096A (en) 1996-07-24
BR9510499B1 (pt) 2009-05-05
DE69535319T2 (de) 2007-07-19
NL300787I1 (no) 2016-04-05
HU222992B1 (hu) 2004-01-28
NO2015027I1 (no) 2015-12-18
CZ196397A3 (en) 1997-10-15
PL194312B1 (pl) 2007-05-31
EP0800536B1 (en) 2006-11-29
NZ301916A (en) 1999-05-28
NO972913D0 (no) 1997-06-20
JP2008029355A (ja) 2008-02-14
CA2208503C (en) 2009-12-01
NL300787I2 (no) 2016-04-05
CN1175263A (zh) 1998-03-04
EP0800536A4 (en) 2004-12-01
LU92912I2 (fr) 2016-02-16
FI972703A (fi) 1997-08-22
EP0800536A2 (en) 1997-10-15
WO1996021000A3 (en) 1996-09-06
DK0800536T3 (da) 2007-04-02
AU708951B2 (en) 1999-08-19
MX9704779A (es) 1997-09-30
FI119374B (fi) 2008-10-31
US6129913A (en) 2000-10-10
PL321088A1 (en) 1997-11-24
CA2208503A1 (en) 1996-07-11
HUT78055A (hu) 1999-07-28
NO324181B1 (no) 2007-09-03
DE69535319D1 (de) 2007-01-11
ES2277336T3 (es) 2007-07-01
ATE346867T1 (de) 2006-12-15
CN100391977C (zh) 2008-06-04
JP2001523083A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
NO972913D0 (no) Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
SE9604793D0 (sv) New polymorphs
GB9619691D0 (en) Antibodies against E-selection
EP1749840A3 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
IL113941A (en) Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ES2131842T3 (es) Compuestos de triazol y su empleo como ligandos de dopamina-d3.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
DE69911401D1 (en) Immunoregulator
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
NO307377B1 (no) Pyridyltioforbindelser for bekjempelse av Helicobacter- bakterier
GB8900812D0 (en) Pharmaceutical method and compositions
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: NUCALA - MEPOLIZUMAB; NAT. REG. NO/DATE: OPPGITT 20151218; FIRST REG. NO/DATE: EU/1/15/1043 20151202

Spc suppl protection certif: 2015027

Filing date: 20151218

MK1K Patent expired
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151218

Spc suppl protection certif: 2015027

Filing date: 20151218

Extension date: 20201222

SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151202

Spc suppl protection certif: 2018035

Filing date: 20181004

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151202

Spc suppl protection certif: 2018035

Filing date: 20181004

Extension date: 20210622

SPCX Expiry of an spc

Free format text: PRODUCT NAME: MEPOLIZUMAB

Spc suppl protection certif: 2015027